Arde­lyx reach­es the 'cap­stone' in their third-straight pos­i­tive PhI­II – but many ques­tions still linger

Arde­lyx has added what it’s call­ing the top­per to the mound of Phase III ev­i­dence that its lead drug can help chron­ic kid­ney dis­ease pa­tients, al­though ques­tions re­main around side ef­fects and how great an im­prove­ment the drug of­fers over the stan­dard-of-care.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER